Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17244
Title: Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy.
Authors: Perucca, Piero;Scheffer, Ingrid E;Harvey, A Simon;James, Paul A;Lunke, Sebastian;Thorne, Natalie;Gaff, Clara;Regan, Brigid M;Damiano, John A;Hildebrand, Michael S;Berkovic, Samuel F;O'Brien, Terence J;Kwan, Patrick
Affiliation: Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia
Epilepsy Research Centre, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
Departments of Paediatrics and Neurology, The Royal Children's Hospital, The University of Melbourne, Melbourne, VIC, Australia
Department of Genetic Medicine, The Royal Melbourne Hospital, Melbourne, VIC, Australia
Centre for Translational Pathology, The University of Melbourne, Melbourne, VIC, Australia
Melbourne Genomics Health Alliance, Melbourne, VIC, Australia
Departments of Medicine and Paediatrics, The University of Melbourne, Melbourne, VIC, Australia
Departments of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Mar-2017
EDate: 2017-02-07
Citation: Epilepsy research 2017; 131: 1-8
Abstract: Driven by advances in genomic technology and reduction in costs, next-generation sequencing (NGS) is venturing into routine clinical care. The 'real-world' clinical utility of NGS remains to be determined in focal epilepsies, which account for 60% of all epilepsies and for which the importance of genetic factors is just beginning to emerge. We investigated the diagnostic yield and management implications of whole exome sequencing (WES)-based screening of selected genes in the routine care of common focal epilepsies suspected to have a genetic basis. We performed WES, followed by targeted analysis of 64 epilepsy genes, on 40 consecutive children and adults enrolled prospectively from routine clinical practice who had MRI-negative focal epilepsy and a family history of febrile seizures or any type of epilepsy in at least one first- or second-degree relative. Exclusion criteria were previous genetic testing, severe intellectual disability and benign focal epilepsies of childhood. 5/40 (12.5%) patients had a pathogenic or likely pathogenic variant, detected in SCN1A, DEPDC5, PCDH19, GABRG2 or NPRL2. Identifying a pathogenic SCN1A variant in a patient with drug-resistant epilepsy prompted to halt presurgical investigations due to concern of unfavorable post-surgical outcome. It also led in the same patient to discontinue long-standing carbamazepine therapy (a potentially aggravating drug in epilepsies due to SCN1A mutations), resulting in complete seizure control. Patients with pathogenic or likely pathogenic variants had a younger median age of seizure onset (range) compared to those without [18 months (8 months-18 years) vs 18 years (18 months-70 years), p=0.02]. Our data demonstrate that WES with targeted gene analysis is an effective diagnostic tool for patients with common focal epilepsies in whom a genetic etiology is suspected. It can also influence clinical decision-making, including antiepileptic drug selection and consideration of epilepsy surgery, hence supporting its incorporation in the routine clinical care of this patient group.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17244
DOI: 10.1016/j.eplepsyres.2017.02.001
ORCID: 0000-0003-4580-841X
0000-0002-2311-2174
PubMed URL: 28199897
Type: Journal Article
Multicenter Study
Pragmatic Clinical Trial
Research Support, Non-U.S. Gov't
Subjects: Epilepsy
Focal
Genetic testing
Genetics
Seizures
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.